These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27678425)

  • 1. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study.
    Zhao XQ; Phan BA; Davis J; Isquith D; Dowdy AA; Boltz S; Neradilek M; Monick EA; Brockenbrough A; Hus-Frechette EE; Albers JJ; Brown BG
    J Clin Lipidol; 2016; 10(5):1091-7. PubMed ID: 27678425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
    Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
    J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
    ; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
    N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
    Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
    J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS).
    Phan BA; Moore AB; Davis J; Pollan LJ; Neradilek B; Brown BG; Zhao XQ
    J Clin Lipidol; 2014; 8(5):489-93. PubMed ID: 25234561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of niacin, statins, and resins in patients with combined hyperlipidemia.
    Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD
    Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
    N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease.
    Abdullah SM; Defina LF; Leonard D; Barlow CE; Radford NB; Willis BL; Rohatgi A; McGuire DK; de Lemos JA; Grundy SM; Berry JD; Khera A
    Circulation; 2018 Nov; 138(21):2315-2325. PubMed ID: 30571575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
    Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
    J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.